Search - tctmd.com

Displaying 41 - 60 of 174

Sort: Relevancy | Date

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

Advertisement

Boston Scientific Scraps Biodegradable Scaffold Program

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

TCTMD’s Top 10 Most Popular Stories for May 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Live From Washington: ACC 2017, Day Two

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content